Agenus Sued by Shareholder for Misleading Investors Over Colorectal Cancer Immuno-Therapy Trial Results

MT NewswiresSep 10 03:02

Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to Be Presented in Oral Session at ESMO 2024

BusinesswireSep 9 19:30

Agenus to Participate in September Investor Conferences

BusinesswireSep 3 19:30

Agenus Analyst Ratings

BenzingaAug 14 20:57 · Ratings

B. Riley Adjusts Price Target on Agenus to $18 From $42, Maintains Buy Rating

MT NewswiresAug 14 19:58 · Ratings

Express News | Agenus Inc : B. Riley Cuts Target Price to $18 From $42

BreakingsAug 14 11:57